Cookies on the Economic Times website

Economic Times has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings,we'll assume that you are happy to receive all cookies on the Economic Times website. However, you can change your cookie setting at any time by clicking on our Cookie Settings at any time.You can also see our Privacy Policy

Back on the growth wagon: Cipla is a favourite of analysts and this week's stock pick

Getty Images

Improving domestic prospects and increasing sales from the US and South Africa raise hopes for the counter.

Synopsis

Cipla reported an FCF of around Rs 3,400 crore in 2019-20 and is expected to report bigger numbers in the coming years due to increased growth rates and cost savings due to domestic synergies. This has made the company a favourite of analysts.

Cipla, the domestic market leader in respiratory and urology segments, did well during the second quarter of 2020-21. It reported y-o-y revenue and adjusted net profit growth of 15% and 41% respectively in this time period. Cipla has eight medicine brands amongst top 100 domestic brands and 22 among top 300 brands. This strong brand power has helped it to report domestic numbers better than the industry average.Cipla is expected to report good

To Read the Full Story, Become an ET Prime Member

Access the exclusive Economic Times stories, Editorial and Expert opinion

Why

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads
  • Comment & Engage with ET Prime community
  • Exclusive invites to Virtual Events with Industry Leaders
  • A trusted team of Journalists & Analysts who can best filter signal from noise